0000000000088385

AUTHOR

Piotr Jankowski

0000-0001-6223-8821

showing 10 related works from this author

Management and predictors of clinical events in 75 686 patients with acute myocardial infarction

2022

Background:Although mortality of patients with acute myocardial infarction (MI) has decreased substantially over the last few decades in many countries MI remains a major threat to public health. Aims:To assess the number and outcomes of patients hospitalized for acute MI in Poland in 2018 as well as proportions of patients participating in cardiac rehabilitation and undergoing invasive cardiac procedures following discharge. Methods:We used public databases. We included all patients hospitalized for acute MI in Poland in 2018 and assessed event-free survival along with uptake of invasive cardiac procedures and cardiac rehabilitation and consultations with cardiologists. Results: A total of…

cardiac rehabilitationcardiovascular eventsPercutaneous Coronary InterventionTreatment OutcomeMyocardial InfarctionAftercareHumansCoronary Artery BypassCardiology and Cardiovascular Medicinemortalitycoronary artery diseasePatient DischargeAgedKardiologia Polska
researchProduct

Innovative Managed Care May Be Related to Improved Prognosis for Acute Myocardial Infarction Survivors

2021

Background: Mortality following discharge in myocardial infarction survivors remains high. Therefore, we compared outcomes in myocardial infarction survivors participating and not participating in a novel, nationwide managed care program for myocardial infarction survivors in Poland. Methods: We used public databases. We included all patients hospitalized due to acute myocardial infarction in Poland between October 1, 2017 and December 31, 2018. We excluded from the analysis all patients aged <18 years as well as those who died during hospitalization or within 10 days following discharge from hospital. All patients were prospectively followed. The primary end point was defined as death …

medicine.medical_specialtybusiness.industryManaged Care ProgramsMyocardial InfarctionPrognosismedicine.diseaseArticleCoronary artery diseasePercutaneous Coronary InterventionInternal medicinemedicineCardiologyHumansManaged careSurvivorsMyocardial infarctionCardiology and Cardiovascular MedicinebusinessCirculation: Cardiovascular Quality and Outcomes
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (<80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active <30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

Do we know more about hypertension in Poland after the May Measurement Month 2017?—Europe

2019

Abstract Elevated blood pressure (BP) is a worldwide burden, leading to over 10 million deaths yearly. May Measurement Month (MMM) is a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for BP screening. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in May 2017. BP measurement, the definition of hypertension and statistical analysis followed the globally approved MMM17 Study Protocol. In Poland 5834 (98.9%, Caucasian) individuals were screened. After multiple imputation, 2601 (35.3%) had hypertension. Of individuals not receiving anti-hypertensive medication, 976 (20.6%) were hype…

medicine.medical_specialtybusiness.industryArticles030204 cardiovascular system & hematologyOverweightmedicine.diseaseObesityElevated blood03 medical and health sciences0302 clinical medicineBlood pressureCardiovascular System & HematologyInternal medicinemedicineStatistical analysis030212 general & internal medicineSystoleUnderweightmedicine.symptomCardiology and Cardiovascular Medicinebusiness1102 Cardiorespiratory Medicine and HaematologyOpportunistic screeningEuropean Heart Journal Supplements
researchProduct

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

2021

Pomimo 30 lat (simwastatyna została dopuszczona w 1991 przez FDA do stosowania klinicznego [1]) starań ekspertów, towarzystw i organizacji pacjenckich zaburzenia lipidowe wciąż stanowią wyzwanie diagnostyczne, ale przede wszystkim terapeutyczne. Dotyczy to zarówno właściwej oceny ryzyka pacjentów, włączenia odpowiedniego leczenia, problemów z jego adherencją, ale także problemów z tak ważnym leczeniem niefarmakologicznym – dietą, redukcją masy ciała czy regularnym wysiłkiem fizycznym [2]. Nie można także umniejszać znaczenia inercji terapeutycznej, czy to polegającej na niewłaściwie dobranej terapii (najczęściej brakiem intensywnego leczenia statynami czy jeszcze rzadziej leczenia skojarzon…

medicine.medical_specialtybusiness.industryInternal medicinemedicinezaburzenia lipidoweGeneral MedicineGuidelinesPTLbusinessWytyczneArchives of Medical Science
researchProduct

Which patients at risk of cardiovascular disease might benefit the most from inclisiran? – The expert opinion of the Polish experts. The compromise b…

2022

It is the statement of the Polish Experts on the group of patients that might benefit the most from inclisiran. We indicated the fastest way to have inclisiran available for the polish patients, with the necessary changes of the existing drug program for PCSK9 inhibitors (B-101), explaining why it is the optimal way, and why, taking into account available EBM data (the ORION program), inclisiran should be added to this program. We also present some perspective on the future necessary changes in the availability of the innovative therapies such us PCSK9 targeted therapy, what, taking into account the effectiveness of LDL-C goal achievement in Poland for very high CVD risk patients (only 17%)…

drug programlipid lowering therapyhigh risk patientsGeneral MedicinePolandinclisiranreimbursementArchives of Medical Science
researchProduct

Comprehensive coordinated care after myocardial infarction (KOS-Zawał) : a patient's perspective

2019

AdultAged 80 and overmedicine.medical_specialtybusiness.industryPerspective (graphical)Myocardial InfarctionMiddle Agedmedicine.diseaseSurveys and QuestionnairesmedicineHumansComprehensive Health CarePolandMyocardial infarctionCardiology and Cardiovascular MedicineIntensive care medicinebusinessAged
researchProduct

May Measurement Month 2018 : an analysis of blood pressure screening campaign results from Poland

2020

Abstract Hypertension remains the most important cardiovascular risk factor in Poland. May Measurement Month is a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for blood pressure (BP) screening and demonstrating the potential of the opportunistic BP measurements. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in 146 sites in May 2018. Blood pressure was measured in 6450 subjects (mean age: 41 ± 15 years; 59% females). After multiple imputation, the age and sex standardized systolic and diastolic BP was 126.7/78.4 mmHg in the whole analysed group, 132.8/81.3 mmHg in subjects tak…

medicine.medical_specialtyDiastoleDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusControlmedicineAcademicSubjects/MED00200Risk factorSystole1102 Cardiorespiratory Medicine and Haematologybusiness.industry030229 sport sciencesArticlesmedicine.diseaseTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningDisease awarenessAlcohol intakeCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct

May Measurement Month 2019 : an analysis of blood pressure screening results from Poland

2021

Abstract May Measurement Month 2019 is the third edition of a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for blood pressure (BP) screening. We present data analysis from Poland. To evaluate the potential of opportunistic BP measurements as a tool for cardiovascular disease prevention programmes. To collect new country data for further annual comparisons. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in 201 sites in May 2019. BP was measured in 7072 subjects (mean age: 54 ± 15 years; 62.3% females). After multiple imputation, the age- and sex-standardized systolic BP (SBP) a…

medicine.medical_specialtyDiastole030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusEpidemiologyControlmedicineAcademicSubjects/MED00200030212 general & internal medicine1102 Cardiorespiratory Medicine and HaematologySecondary preventionbusiness.industryMean ageArticlesmedicine.diseaseTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningDisease awarenessDisease preventionCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct

Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study)

2022

Abstract Aims The coronavirus disease‐2019 (COVID‐19) pandemic has changed the landscape of medical care delivery worldwide. We aimed to assess the influence of COVID‐19 pandemic on hospital admissions and in‐hospital mortality rate in patients with acute heart failure (AHF) in a retrospective, multicentre study. Methods and results From 1 January 2019 to 31 December 2020, a total of 101 433 patients were hospitalized in 24 Cardiology Departments in Poland. The number of patients admitted due to AHF decreased by 23.4% from 9853 in 2019 to 7546 in 2020 (P < 0.001). We noted a significant reduction of self‐referrals in the times of COVID‐19 pandemic accounting 27.8% (P < 0.001), with increase…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Heart failureMedical careLevodopaCOVID‐19Internal medicinePandemicmedicineHumansDiseases of the circulatory (Cardiovascular) systemIn patientPandemicsRetrospective StudiesSARS-CoV-2business.industryMortality rateCarbidopaCOVID-19Original Articlesmedicine.diseaseIn‐hospital mortalityHospitalizationDrug CombinationsIn-hospital mortalityRC666-701Heart failureConcomitantAcute DiseaseOriginal ArticleCardiology and Cardiovascular MedicinebusinessHospital stayESC heart failure
researchProduct